In a global first for Africa, UCT is participating in a clinical trial to reprogramme genes and halt hereditary angioedema.

Crispr Therapeutics' current revenue from CASGEVY is limited by high costs, profit-sharing, and logistical hurdles. Click ...

Shares of CRISPR Therapeutics CRSP have risen 14% over the past month, likely driven by encouraging results from the first ...

SNIPR Biome ApS (“SNIPR”), the company pioneering the development of precision medicines using CRISPR technology for microbial gene therapy, today announced that the first patient has been dosed in ...

In a Phase Ib trial, researchers will compare SNIPR001's activity against placebo in around two dozen patients who also receive a standard antibiotic.

This video explores how CRISPR, the groundbreaking gene-editing technology, is being used in clinical trials to partially restore sight in people with inherited retinal diseases. We break down the ...

Victoria Gray, the first person cured of sickle cell using CRISPR gene editing therapies, spoke in Fargo about her journey and the need to lower the $2M treatment cost.

TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal ...

Epigenetic changes do not alter the genetic code itself, but by changing how DNA is organized within the cell, epigenetic ...

Medable Inc., a leading technology platform provider for decentralized clinical trials, today unveiled its digital-first Long-Term Follow-Up (LTFU) model for cell and gene therapy (CGT) trials.